Canada Markets closed

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1400-0.0050 (-3.45%)
At close: 03:31PM EDT
Full screen
Previous Close0.1450
Open0.1400
Bid0.1400 x N/A
Ask0.1500 x N/A
Day's Range0.1400 - 0.1450
52 Week Range0.1050 - 1.2400
Volume21,275
Avg. Volume251,461
Market Cap9.64M
Beta (5Y Monthly)N/A
PE Ratio (TTM)3.50
EPS (TTM)0.0400
Earnings DateOct 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PharmaTher Announces Positive Results from Study of KETABET™ for Depression

    KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning a Phase 2 clinical study to incorporate KETABET™ in its proprietary microneedle patch for depression TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine ph

  • GlobeNewswire

    PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

    CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device prototype worn on a person CCBIO’s Felice Dose on-body wearable device prototype worn on a person Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty ketamine products for mental health, neurological and pain disorders TORONTO,

  • GlobeNewswire

    PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

    TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the United States Patent and Trademark Office granted US Patent No: 11,286,230, titled “Ketamine Flow Synthesis” (the “Patent”), which refers to a continuous-flow process technology for the preparation of ketamine and ketamine analogs. The Company gained exclusive worldwide development and commer